Affiliation:
1. Theranos, Inc., 3200 Hillview Ave., Palo Alto, CA 94304, USA.
Abstract
Personalized medicine is recognized as being a significant part of the solution for providing better healthcare outcomes. However, there are multiple challenges to its adoption from many healthcare stakeholders. The challenges are not technological, but rather involve the development of the appropriate business model, such that all stakeholders can have the necessary incentives to justify adoption. From a commercial perspective, two different industries with distinct business models are involved: pharma and the diagnostics industry. In order for personalized medicine to have its desired impact, it is necessary that innovative business models from various sectors within healthcare are developed. The problem is that different stakeholders have different motivations, but it is all ultimately driven by economic decisions, and empowering of the patient/consumer will also be a significant factor.
Subject
Pharmacology,Molecular Medicine,General Medicine
Reference21 articles.
1. SannesLJ:Molecular diagnostics: a rapidly shifting commercial and technology landscape. Insight Pharma Reports(2007).
2. SannesLJ:Molecular diagnostics: a dynamic and rapidly broadening market. Insight Pharma Reports(2009).
3. RubensteinK:Multiplex assays: technologies, applications, and markets. Advances Reports.Cambridge Healthtech Associates, MA, USA (2006).
4. The microeconomics of personalized medicine: today's challenge and tomorrow's promise
5. Kushner D: When man and machine mergewww.rollingstone.com/news/story/25939914/when_man__machine_merge
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献